METALEX INTERSECTS SULPHIDES WITH DRILLING AT B3 CLAIM BLOCK IN QUEBEC
At target O the Company has completed three holes testing a steeply-dipping, wide conductive zone associated with the northeast contact of a strong magnetic anomaly.
Two of these holes intersected sulphides within a magmatic gneiss. The sulphides are predominantly pyrite and pyrrhotite with traces of arsenopyrite.
Initial photos of some of the core from these intervals are set out below along with selected enlargements. These photos will be posted to Metalex's website (https://metalexventures.com/quebec-property/). Note that it is too early to determine whether the orientation of the sulphides and as such the intervals mentioned are core lengths rather than true widths.
Hole QC-B3-25-005 was drilled at a -45 degree dip and intersected sulphides from 41.45m to 61.26m. Photos from this hole are presented below.
Hole QC-B3-25-006 was drilled at a -65 degree dip from the same collar as QC-B3-25-005. Sulphides were intersected from 41.76m to 58.52m. Photos from this hole are presented below.
Hole QC-B3-25-007 was drilled vertically, and did not encounter the same sulphides as the two holes above.
The 24,322 hectare B3 claim block was staked due to anomalous copper-nickel-cobalt and gold results of the Company's regional heavy mineral sampling program. Metalex has undertaken a VTEM and magnetic airborne geophysical survey over its B3 claim block by Geotech Ltd. The location of the claim block is shown in Map 1.
The technical information and results reported here have been approved by Mr. Chad Ulansky P.Geo., President and CEO of the Company and a Qualified Person under National Instrument 43-101, who is responsible for the technical content of this release.
Signed,
Charles Fipke
Dr. Charles Fipke C.M.
Chairman and Director
FORWARD LOOKING STATEMENTS: Certain of the statements and information in this press release constitute "forward-looking statements" or "forward-looking information", including statements regarding the expected use of proceeds of the private placement. Further, any statements or information that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects", "anticipates", "believes", "plans", "estimates", "intends", "targets", "goals", "forecasts", "objectives", "potential" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements or information. The Company's forward-looking statements and information are based on the assumptions, beliefs, expectations and opinions of management as of the date of this press release, and other than as required by applicable securities laws, the Company does not assume any obligation to update forward-looking statements and information if circumstances or management's assumptions, beliefs, expectations or opinions should change, or changes in any other events affecting such statements or information. For the reasons set forth above, investors should not place undue reliance on forward-looking statements and information.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
24 minutes ago
- Cision Canada
VABYSMO® (faricimab injection) Now Publicly Funded For Macular Edema Secondary to Retinal Vein Occlusion (RVO) and Pre-Filled Syringe (PFS) in Quebec Français
Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs MISSISSAUGA, ON, Aug. 15, 2025 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that VABYSMO ® (faricimab injection) is now publicly funded for macular edema secondary to retinal vein occlusion (RVO) on the Régie de l'assurance maladie du Québec (RAMQ) list of medications. 1 This latest update also includes funding for Vabysmo in a 6.0 mg single-use pre-filled syringe (PFS), providing an additional option and expanded access for patients in Quebec. Vabysmo received Health Canada authorization for treatment of macular edema secondary to retinal vein occlusion (RVO) in July 2024, and the approval of the PFS format in December 2024. 2 "This expansion in coverage for people with RVO in Quebec is welcome news in our mission to advance eye care and provide innovative solutions for people living with serious retinal conditions," said Carlene Todd, Vice President, Access at Roche Pharmaceuticals Canada. "We are deeply committed to ensuring equitable and timely access to our treatments, ensuring that provinces across the country prioritize access to innovative medicines that will ultimately improve the lives of people impacted by vision loss." With this latest listing, Vabysmo is now covered in Quebec for all three of its indications and in both formats, including neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and the latest, macular edema secondary to retinal vein occlusion (RVO). These leading causes of vision loss affect around 70 million people worldwide and can have a serious impact on patients, their families, and caregivers. 3,4,5,6 "The recent reimbursement for RVO in Quebec is a significant step forward for people living with the condition," said Dr. Ananda (Andy) Kalevar, Associate Professor, Department of Ophthalmology at Sherbrooke University, Quebec. "It gives ophthalmologists a valuable treatment option and provides patients with access to a medication that may ultimately offer the best outcomes for their vision." Roche Canada is committed to continuing to work with remaining provincial jurisdictions to make Vabysmo available through public and private drug plans for those living with RVO. About retinal vein occlusion (RVO) RVO is the second most common cause of vision loss due to retinal vascular conditions. It affects an estimated 28 million adults globally, mainly those aged 60 or older, and can lead to severe and sudden vision loss. 3,7 There are two main types of RVO: branch RVO (BRVO), which affects more than 23 million people globally and occurs when one of the four smaller 'branches' of the main central retinal vein becomes blocked; and central RVO (CRVO), which is less common, affecting more than four million people worldwide, and occurs when the eye's central retinal vein becomes blocked. 3,8 The levels of Vascular Endothelial Growth Factor A (VEGF-A) and angiopoietin-2 (Ang-2) are elevated in RVO and it is thought that their increased expression drives disease progression. 9,10 RVO typically results in sudden, painless vision loss in the affected eye because the vein blockage restricts normal blood flow in the affected retina, resulting in ischemia, bleeding, fluid leakage and retinal swelling called macular edema. 7,11,8 The safety and efficacy of Vabysmo for the treatment of macular edema secondary to retinal vein occlusion (RVO) were assessed in two randomised, multi-centre, double-masked, studies in patients with macular edema secondary to BRVO (BALATON) or CRVO/hemiretinal vein occlusion (HRVO) (COMINO). Between Week 24 and Week 72, for patients who received faricimab Q4W/faricimab PTI, 49% of patients in BALATON and 34% of patients in COMINO completed at least one cycle of every 12 weeks (Q12W) and maintained ≥ Q12W dosing without an interval reduction below Q12W through Week 68; 32% of patients in BALATON and 24% of patients in COMINO completed 2 cycles of Q16W through Week 72. 2 About Vabysmo ® (faricimab injection) Vabysmo is a humanized bispecific immunoglobulin G1 (IgG1) antibody that acts through inhibition of both Ang-2 and vascular endothelial growth factor A (VEGF-A). By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to increase vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with wet AMD, DME, and RVO. 2 In Canada, Vabysmo is authorized for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). 2 To date, Vabysmo is approved in more than 100 countries for DME and nAMD, and in over 30 countries for macular edema following retinal vein occlusion (RVO). 12,13,14,15,16,17 About Roche Canada At Roche Canada, patients and science are at the heart of everything we do. Our passion for science and our commitment to relentlessly pursuing the impossible for patients have made us one of the world's leading pharmaceutical, in-vitro diagnostics, and diabetes care management companies. With our combined strength in diagnostics and pharmaceuticals, we're driving healthcare forward, while ensuring we deliver meaningful benefits for patients and sustainable healthcare systems. We are committed to creating a world where we all have more time with the people we love. And we're adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries. Having the courage to reinvent ourselves and question the status quo is what patients and healthcare systems expect from Roche - and our commitment is as strong today as it was on the first day of our Canadian journey in 1931. Today, Roche Canada employs nearly 2,000 people at its offices in Mississauga, Ontario, in Laval, Quebec, and across the country from coast to coast to coast. For more information, please visit or follow Roche Canada on LinkedIn. References [1] RAMQ List of medications. Available at: Accessed on August 14, 2025. [2] Vabysmo Product Monograph, July 25, 2025 [3] Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019; 9:010427. Song P, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019; 9:010427. [4] Yau JWY, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35:556–64. [5] Connolly E, et al. Prevalence of age-related macular degeneration associated genetic risk factors and 4-year progression data in the Irish population. Br J Ophthalmol. 2018;102:1691–95. [6] Bright Focus Foundation. Age-Related Macular Degeneration: Facts & Figures [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [7] Moorfields Eye Hospital, United Kingdom National Health Service Foundation Trust. RVO [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [8] Campochiaro P. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015; 49:67-81. [9] Joussen et al. Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021; 35:1305-1316. [10] Regula JT, et al. Targeting key angiogenic pathways with a bispecific CrossMab optimised for neovascular eye diseases. EMBO Molecular Medicine. 2016; 8:1265–88. [11] Schmidt-Erfurth U, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica. 2019; 242:123-162. [12] U.S. Food and Drug Administration (FDA). Highlights of prescribing information, aflibercept 2 mg. 2022. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [13] FDA. Highlights of prescribing information, Vabysmo. 2022. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [14] FDA approves Genentech's Vabysmo for the treatment of RVO [Internet; cited August 2025]. Available from: Accessed on August 6, 2025 [15] Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with RVO. [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [16] European Medicines Agency. Summary of product characteristics, Vabysmo, 2022 [Internet; cited August 2025]. Available from: Accessed on August 6, 2025. [17] Roche Data on File SOURCE Hoffmann-La Roche Limited (Roche Canada)
Globe and Mail
24 minutes ago
- Globe and Mail
FUTR Surpasses 1,000,000 Transactions and USD$380 Million in Payments Volume With FinWise Bank
The FUTR Corporation (TSXV: FTRC) (OTCQB: FTRCF) ("FUTR" or the "Company"), a consumer-centric platform for data valuation and monetization is pleased to announce a major operational milestone, passing 1,000,000 transactions and USD$380 million in payment transaction volume using FinWise Bank's payment rails. The platform has processed more than $3 billion in payments for nearly 300,000 users through automated cash flow and loan management. Since March 2024, these transactions have leveraged FinWise Bank's payment services, including multiple cost-efficient payment rails. FUTR also maintains monthly deposits at FinWise from transiting payments as part of the overall relationship. As FUTR expands into new consumer markets and introduces the AI Agent App, it expects significant growth in transaction volume, processed dollars, and deposits on its banking partner platforms. With new partners and a deepening of the FinWise partnership, FUTR also anticipates greater payment automation. Leveraging FinWise's efficient and cost-effective platform, FUTR earns convenience fees on transactions and basis points on transiting deposits. 'This milestone demonstrates consumers' strong trust in FUTR to deliver real savings and convenience with our automated cash management platform coupled with smart payment rails,' said Mindy Bruns, Chief Business Officer at FUTR. 'A major part of this value is access to solid infrastructure from FinWise. We're preparing for substantial growth in users and features in the months ahead.' 'We appreciate that FUTR recognizes our vision and the value of our payments platforms,' stated Robert Keil, SVP and Chief Fintech Officer at FinWise Bank. 'We are pleased with the customer migration and see a lot of value in FUTR's consumer-focused services. This partnership with FUTR also gives FinWise the opportunity to generate lower-cost deposits.' About The FUTR Corporation FUTR's AI Agent App is focused on putting money back in consumer's wallets through a unique data monetization rewards system, personalized offers as well as agent-driven smart payment management. The FUTR AI Agent App will allow Enterprises to get rewarded for contributing consented Consumer data to the Agent and allow Brands to leverage this data to improve personalization and customer acquisition. About FinWise Bank Corp. FinWise provides Banking and Payments solutions to fintech brands. Its existing Strategic Program Lending business, conducted through scalable API-driven infrastructure, powers deposit, lending and payments programs for leading fintech brands. As part of Strategic Program Lending, FinWise also provides a Credit Enhanced Balance Sheet Program, which addresses the challenges that lending and card programs face diversifying their funding sources and managing capital efficiency. In addition, FinWise manages other Lending programs such as SBA 7(a), Owner Occupied Commercial Real Estate, and Leasing, which provide flexibility for disciplined balance sheet growth. The Company is also expanding and diversifying its business model by incorporating Payments (MoneyRails ™) and BIN Sponsorship offerings. Through its compliance oversight and risk management-first culture, the Company is well positioned to guide fintechs through a rigorous process to facilitate regulatory compliance. Forward-Looking Statements This news release may contain forward-looking statements (within the meaning of applicable securities laws) which reflect the Company's current expectations regarding future events. Forward-looking statements are identified by words such as 'believe', 'anticipate', 'project', 'expect', 'intend', 'plan', 'will', 'may', 'estimate' and other similar expressions. These statements are based on the Company's expectations, estimates, forecasts, and projections and include, without limitation, statements regarding the future success of the Company's business. The forward-looking statements in this news release are based on certain assumptions. The forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements. Readers, therefore, should not place undue reliance on any such forward-looking statements. Further, these forward-looking statements are made as of the date of this news release and, except as expressly required by applicable law, the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cision Canada
an hour ago
- Cision Canada
CT REIT Declares Distribution for the Period of August 1, 2025 to August 31, 2025 Français
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./ TORONTO, Aug. 15, 2025 /CNW/ - CT Real Estate Investment Trust ("CT REIT") (TSX: announced today that the trustees of CT REIT have declared a distribution for the period of August 1, 2025 to August 31, 2025 of $0.07903 per trust unit, payable September 15, 2025 to unitholders of record on August 29, 2025. This distribution, if annualized, would represent a rate of $0.94836 per annum. About CT REIT CT REIT is an unincorporated, closed-end real estate investment trust formed to own income-producing commercial properties located primarily in Canada. Its portfolio is comprised of over 375 properties totalling more than 31 million square feet of GLA, consisting primarily of net lease single-tenant retail properties located across Canada. Canadian Tire Corporation, Limited is CT REIT's most significant tenant. For more information, visit SOURCE CT Real Estate Investment Trust (CT REIT)
